Project Grant HT94252510924
- This $240,897 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports transcriptomic and epigenomic profiling research on subependymal giant cell astrocytoma at Duke University. The research, which will be conducted from August 1, 2025 to July 31, 2027, aims to investigate the mechanisms of this rare brain tumor at the single-cell level. This project aligns with the program's objective to transform healthcare for...
- The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
- This Project Grant award for $847,875.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at the University of Virginia to investigate Schwann cell-tumor microenvironment interactions in neurofibroma development. The award has a performance period from September 1, 2025 to August 31, 2028. The Military Medical Research and Development program funds a diverse portfolio of scientific investigations across...
- This Project Grant award of $999,999.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the University of California, San Francisco (UCSF) in conducting advanced biomedical research on cell-free DNA epigenetic biomarkers in multiple sclerosis. The research aims to transform healthcare for military service members, veterans, and the broader public by investigating innovative approaches to the prevention, diagnosis, and management...
- The Defense Health Agency awarded Emory University a $160,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of April 1, 2023 through March 31, 2025. The grant will support GENOME-WIDE ANALYSES OF PROTEIN-DNA INTERACTION USING LONG-READ SEQUENCING. Through this funding, Emory University will conduct research using long-read sequencing to analyze protein-DNA interactions on a genome-wide scale. The Military Medical Research and Development...
- The federal Project Grant award of $232,878 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will fund research by The Johns Hopkins University to explore the role of epitranscriptomics in the evolution of neuroendocrine prostate cancer. The award, effective June 1, 2025 through May 31, 2027, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The federal grant...
- This Project Grant, awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), provides $625,994 to Emory University to support research on novel cell therapy approaches for neuroblastoma. The project aims to advance the development of new treatments for this type of pediatric cancer, which is a priority area for military medical research. Emory University, a leading academic research institution, is well-positioned to conduct this work,...
- The Defense Health Agency awarded Emory University a $156,500 project grant under the Military Medical Research and Development program to support research on core transcription factors in regenerative medicine and cancer. The one-year award beginning September 30, 2023 will fund investigation into medical solutions for the battlefield by transforming healthcare through innovative biomedical research. Specifically, Emory University will conduct research on core transcription factors as they...
- This Project Grant award of $1,155,518.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports in-vivo neuroepigenetics research in combat veterans with repeated blast exposure at the Massachusetts General Hospital (MGH) in Boston, MA. The award, with a performance period from September 1, 2025 to August 31, 2028, will enable advanced biomedical research at MGH, a renowned academic medical center, to investigate innovative approaches...
- Emory University was awarded a $159,929 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund whole-genome structural variation and CpG methylation analyses through long-read sequencing from April 1, 2023 to March 31, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...
The Project Grant award titled "ESTABLISHING EPIGENETIC MARKERS IN NEUROFIBROMATOSIS" is funded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $156,049 award to Emory University will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the general public. The research will focus on investigating epigenetic markers associated with neurofibromatosis, a genetic disorder that causes tumors to grow on nerves. This project grant runs from October 1, 2025 to September 30, 2026 and is part of the Defense Health Agency's broader strategy to fund innovative medical research across diverse domains, including cancer, neuroscience, and genetic disorders, to address critical health challenges.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $156.0k | 8/12/25 |